Loading...
Loading...
CLRB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 11.9M |
| Operating I/L | -12.0M |
| Other Income/Expense | -9.6M |
| Interest Income | 0.3M |
| Pretax | -21.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -21.6M |
Cellectar Biosciences, Inc. is a clinical biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for cancer treatment. The company's lead product is CLR 131, a phospholipid drug conjugate (PDC) candidate currently in Phase 2 clinical studies for various cancers, including Waldenstrom's macroglobulinemia, multiple myeloma, pediatric cancers, and head and neck cancers. Additionally, Cellectar Biosciences is developing CLR 1900, a PDC chemotherapeutic program for solid tumors, and has collaborative PDC programs with several partners. The company generates revenue through the development and commercialization of its drug candidates for cancer therapy.
